Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.

作者: Simone Dario Scilabra , Armando Rossello , Elisa Nuti , Doretta Cuffaro , Simone Bonelli

DOI: 10.3390/MOLECULES26040944

关键词: DiseaseContext (language use)DisintegrinComputational biologyMatrix metalloproteinaseTransmembrane proteinTumor necrosis factor alphaIn vivoImmune systemBiology

摘要: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as tumor necrosis factor convertase, it considered a major drug target, especially in context inflammatory diseases cancer. Nevertheless, development drugs targeting ADAM17 harder than expected. This generally due to multifunctionality, with over 80 different transmembrane proteins other α (TNF) being released by ADAM17, structural similarity metalloproteinases. review provides an overview roles disease effects ablation number vivo models pathological conditions. Furthermore, here, we comprehensively encompass approaches that have developed accomplish selective inhibition, from newest non-zinc-binding synthetic inhibitors exploitation iRhom2 specifically target immune cells.

参考文章(216)
Sara L. Montgomery, Michael A. Mastrangelo, Diala Habib, Wade C. Narrow, Sara A. Knowlden, Terry W. Wright, William J. Bowers, Ablation of TNF-RI/RII Expression in Alzheimer's Disease Mice Leads to an Unexpected Enhancement of Pathology The American Journal of Pathology. ,vol. 179, pp. 2053- 2070 ,(2011) , 10.1016/J.AJPATH.2011.07.001
Tom W J Huizinga, Mohamed M Thabet, Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Current opinion in investigational drugs. ,vol. 7, pp. 1014- 1019 ,(2006)
F Caiazza, P M McGowan, M Mullooly, A Murray, N Synnott, N O'Donovan, L Flanagan, C J Tape, G Murphy, J Crown, M J Duffy, Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells British Journal of Cancer. ,vol. 112, pp. 1895- 1903 ,(2015) , 10.1038/BJC.2015.163
Keisuke Horiuchi, Tokuhiro Kimura, Takeshi Miyamoto, Kana Miyamoto, Haruhiko Akiyama, Hironari Takaishi, Hideo Morioka, Takashi Nakamura, Yasunori Okada, Carl P. Blobel, Yoshiaki Toyama, Conditional Inactivation of TACE by a Sox9 Promoter Leads to Osteoporosis and Increased Granulopoiesis via Dysregulation of IL-17 and G-CSF Journal of Immunology. ,vol. 182, pp. 2093- 2101 ,(2009) , 10.4049/JIMMUNOL.0802491
Heather A. Arnett, Jeff Mason, Mike Marino, Kinuko Suzuki, Glenn K. Matsushima, Jenny P.-Y. Ting, TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nature Neuroscience. ,vol. 4, pp. 1116- 1122 ,(2001) , 10.1038/NN738
Ming Cai, Zhiqiang Wang, Jiru Zhang, Huan Zhou, Linfang Jin, Ruizhen Bai, Yuan Weng, Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma Cellular Physiology and Biochemistry. ,vol. 36, pp. 1175- 1185 ,(2015) , 10.1159/000430288
Jian-Quan Shi, Bian-Rong Wang, Wei-Wei Jiang, Jun Chen, Yin-Wei Zhu, Ling-Ling Zhong, Ying-Dong Zhang, Jun Xu, COGNITIVE IMPROVEMENT WITH INTRATHECAL ADMINISTRATION OF INFLIXIMAB IN A WOMAN WITH ALZHEIMER'S DISEASE Journal of the American Geriatrics Society. ,vol. 59, pp. 1142- 1144 ,(2011) , 10.1111/J.1532-5415.2011.03445.X
Kai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, Wolfgang Eberhardt, Michel Mittelbronn, Patrick N. Harter, Eva Juengel, Roman Blaheta, Josef Pfeilschifter, Paul Gutwein, MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia. ,vol. 15, pp. 218- 230 ,(2013) , 10.1593/NEO.121222
Harald Wajant, Peter Scheurich, TNFR1‐induced activation of the classical NF‐κB pathway FEBS Journal. ,vol. 278, pp. 862- 876 ,(2011) , 10.1111/J.1742-4658.2011.08015.X